Cargando…
The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data
Two mRNA COVID-19 vaccines (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) and one viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) are authorized in the US to hinder COVID-19 infections. We analyzed severe and common adverse events in response to COVID-19 vaccines using real-wor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879025/ https://www.ncbi.nlm.nih.gov/pubmed/35214779 http://dx.doi.org/10.3390/vaccines10020320 |
_version_ | 1784658800027893760 |
---|---|
author | Sa, Soonok Lee, Chae Won Shim, Sung Ryul Yoo, Hyounggyoon Choi, Jinwha Kim, Ju Hee Lee, Kiwon Hong, Myunghee Han, Hyun Wook |
author_facet | Sa, Soonok Lee, Chae Won Shim, Sung Ryul Yoo, Hyounggyoon Choi, Jinwha Kim, Ju Hee Lee, Kiwon Hong, Myunghee Han, Hyun Wook |
author_sort | Sa, Soonok |
collection | PubMed |
description | Two mRNA COVID-19 vaccines (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) and one viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) are authorized in the US to hinder COVID-19 infections. We analyzed severe and common adverse events in response to COVID-19 vaccines using real-world, Vaccine Adverse Effect Reporting System (VAERS) data. From 14 December 2020 to 30 September 2021, 481,172 (50.7 ± 17.5 years, males 27.89%, 12.35 per 100,000 people) individuals reported adverse events (AEs). The median time to severe AEs was 2 days after injection. The risk of severe AEs following the one viral vector vaccine (OR = 1.044, 95% CI = 1.005–1.086) was significantly higher than that after the two mRNA vaccines, and the risk among males (OR = 1.374, 95% CI = 1.342–1.406) was higher than among females, except for anaphylaxis. For common AEs, however, the risk to males (OR = 0.621, 95% CI = 0.612–0.63) was lower than to females. In conclusion, we provided medical insight and clinical guidance about vaccine types by characterizing AEs using real-world data. In particular, COVID-19 mRNA vaccines are safer than viral vector vaccines with regard to coagulation disorders, whereas inflammation-related AEs are lower in the viral vaccine. The risk–benefit ratio of vaccines should be carefully considered, and close monitoring and management of severe AEs is needed. |
format | Online Article Text |
id | pubmed-8879025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88790252022-02-26 The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data Sa, Soonok Lee, Chae Won Shim, Sung Ryul Yoo, Hyounggyoon Choi, Jinwha Kim, Ju Hee Lee, Kiwon Hong, Myunghee Han, Hyun Wook Vaccines (Basel) Article Two mRNA COVID-19 vaccines (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) and one viral vector vaccine (JNJ-78436735, Janssen/Johnson and Johnson) are authorized in the US to hinder COVID-19 infections. We analyzed severe and common adverse events in response to COVID-19 vaccines using real-world, Vaccine Adverse Effect Reporting System (VAERS) data. From 14 December 2020 to 30 September 2021, 481,172 (50.7 ± 17.5 years, males 27.89%, 12.35 per 100,000 people) individuals reported adverse events (AEs). The median time to severe AEs was 2 days after injection. The risk of severe AEs following the one viral vector vaccine (OR = 1.044, 95% CI = 1.005–1.086) was significantly higher than that after the two mRNA vaccines, and the risk among males (OR = 1.374, 95% CI = 1.342–1.406) was higher than among females, except for anaphylaxis. For common AEs, however, the risk to males (OR = 0.621, 95% CI = 0.612–0.63) was lower than to females. In conclusion, we provided medical insight and clinical guidance about vaccine types by characterizing AEs using real-world data. In particular, COVID-19 mRNA vaccines are safer than viral vector vaccines with regard to coagulation disorders, whereas inflammation-related AEs are lower in the viral vaccine. The risk–benefit ratio of vaccines should be carefully considered, and close monitoring and management of severe AEs is needed. MDPI 2022-02-17 /pmc/articles/PMC8879025/ /pubmed/35214779 http://dx.doi.org/10.3390/vaccines10020320 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sa, Soonok Lee, Chae Won Shim, Sung Ryul Yoo, Hyounggyoon Choi, Jinwha Kim, Ju Hee Lee, Kiwon Hong, Myunghee Han, Hyun Wook The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data |
title | The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data |
title_full | The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data |
title_fullStr | The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data |
title_full_unstemmed | The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data |
title_short | The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data |
title_sort | safety of mrna-1273, bnt162b2 and jnj-78436735 covid-19 vaccines: safety monitoring for adverse events using real-world data |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879025/ https://www.ncbi.nlm.nih.gov/pubmed/35214779 http://dx.doi.org/10.3390/vaccines10020320 |
work_keys_str_mv | AT sasoonok thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT leechaewon thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT shimsungryul thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT yoohyounggyoon thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT choijinwha thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT kimjuhee thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT leekiwon thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT hongmyunghee thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT hanhyunwook thesafetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT sasoonok safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT leechaewon safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT shimsungryul safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT yoohyounggyoon safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT choijinwha safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT kimjuhee safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT leekiwon safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT hongmyunghee safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata AT hanhyunwook safetyofmrna1273bnt162b2andjnj78436735covid19vaccinessafetymonitoringforadverseeventsusingrealworlddata |